PepEvolutionSelank
A Russian-developed anxiolytic/nootropic peptide with a domestic regulatory record but little Western trial evidence.
Verdict — C · Emerging / Mixed
A reasonably benign anxiolytic peptide with a Russian regulatory track record, but the evidence base barely extends beyond domestic studies and sourcing is unverified. A C — interesting and low-burden for the experienced, not a settled recommendation.
Overview
Selank is a synthetic heptapeptide derived from the immunomodulator tuftsin, developed in Russia as an anxiolytic with reported nootropic and immunotropic effects. It carries a Russian regulatory registration and a small domestic clinical literature suggesting benefit in anxiety, but it has essentially no Western registered-trial evidence and the human data are limited and hard to reproduce internationally. Tolerability appears good in the available studies; sourcing is research-grade and COA verification is the limiting factor.
PepScore Breakdown — the four axes
Evidence
35% weightHow strong is the published human science?
Sourcing & COA
30% weightOur moatCan a buyer obtain an independently-verified, high-purity version? — our proprietary layer.
Safety & Risk
25% weightWhat is the real-world harm potential?
Practicality
10% weightHow easy is it to actually run a verified version?
Sources & Citations
Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.
Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.